Neonatal Abstinence Syndrome: Federal Prevention Role and Related Data


Russell Bailey (Editor)

Series: Public Health in the 21st Century
BISAC: MED058080

The prenatal use of opioids, including heroin and opioids prescribed for pain management, can produce a withdrawal condition in newborns known as Neonatal abstinence syndrome (NAS). These and other substances pass through the placenta that connects the baby to its mother in the womb.

The baby becomes addicted along with the mother. A recent study found that cases of NAS have tripled over the last decade and that treatment costs for newborns with NAS—most of which are paid by Medicaid—are more than five times the cost of treating other newborns at birth.

This book examines federally funded research, federal programs, and other federal agency efforts related to prenatal opioid use or NAS; gaps identified by federal agency officials and experts in efforts to address prenatal opioid use or NAS; and how federal efforts to address prenatal opioid use or NAS are planned and coordinated. It also discusses symptoms and characteristics of NAS.
(Imprint: Novinka)

Table of Contents

Table of Contents


Chapter 1 –

Prenatal Drug Use And Newborn Health: Federal Efforts Need Better Planning and Coordination (pp. 1-60)

United States Government Accountability Office

Chapter 2 –

Neonatal Abstinence Syndrome (pp. 61-66)

Kimberly G. Lee

Chapter 3 –

Infant and Maternal Characteristics in Neonatal Abstinence Syndrome: Selected Hospitals in Florida, 2010–2011 (pp. 67-76)

Jennifer N. Lind, Pharm, Emily E. Petersen et al.


Chapter 4 –

Opioid Prescription Claims Among Women of Reproductive Age: United States, 2008–2012 (pp. 77-88)

Elizabeth C. Ailes, April L. Dawson, Jennifer N. Lind et al.


Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!